Palisade Bio (DB:7NS0) - Prezzo delle azioni, notizie e analisi

7NS0 Panoramica delle azioni

A clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. Maggiori dettagli

7NS0 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 18.7% all'anno per i prossimi 3 anni

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Le azioni sono altamente illiquide

+ 2 più rischi

Palisade Bio, Inc. Concorrenti

MPH Health Care

DB:93M1

€105.3m

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Palisade Bio
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$5.01
Massimo di 52 settimane	US$30.82
Minimo di 52 settimane	US$4.75
Beta	1.29
1Variazione di 1 mese	0%
Variazione a 3 mesi	0.12%
Variazione di 1 anno	-78.46%
3Variazione a 3 anni	-99.77%
Variazione a 5 anni	n/a
Variazione dall'IPO	-99.89%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	7NS0	DE Pharmaceuticals	DE Mercato
7D	0%	-1.2%	-0.02%
1Y	-78.5%	-20.1%	8.2%

Ritorno vs Industria: 7NS0 ha avuto una performance inferiore rispetto al German Pharmaceuticals che ha registrato un rendimento -20.1 % nell'ultimo anno.

Rendimento vs Mercato: 7NS0 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.2 % nell'ultimo anno.

Volatilità dei prezzi

Is 7NS0's price volatile compared to industry and market?
7NS0 volatility
7NS0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 7NS0 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 7NS0 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	9	J. Finley	www.palisadebio.com

Palisade Bio, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Palisade Bio con la sua capitalizzazione di mercato?
7NS0 statistiche fondamentali
Capitalizzazione di mercato	€3.96m
Guadagni(TTM)	-€12.57m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.3x

Rapporto P/E

7NS0 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
7NS0 Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$13.50m
Guadagni	-US$13.50m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-14.42
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato 7NS0 nel lungo periodo?

Vedi performance storica e confronto

7NS0 Panoramica delle azioni

Analisi del rischio

Palisade Bio, Inc. Concorrenti

DB:93M1

€105.3m

XTRA:B8FK

€16.4m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

Recent updates

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108

Palisade Bio, Inc. announced that it has received $3.999943 million in funding

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio, Inc. Announces Advisory Board Appointments

New major risk - Share price stability

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Revenue and earnings growth

Palisade Bio Receives Non-Compliance Notice from Nasdaq

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

New major risk - Market cap size

Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Palisade Bio, Inc. Announces Board Appointments

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.220371 million.

Palisade Bio, Inc. announced that it has received funding

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

U.S. Food and Drug Administration Grants Fast Track Designation to Palisade Bio for LB1148 for Accelerated Return of Bowel Function Following GI Surgery

Palisade Bio Appoints Herbert B. Slade MD, FAAAAI as Chief Medical Officer

Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer

Palisade Bio, Inc. Announces Executive Changes

Palisade Bio, Inc. Announces Chief Executive Officer Transition

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons Clinical Congress 2022

Palisade Bio, Inc. Announces the Commencement of Patient Enrollment and Dosing in Its Pivotal Phase 3 Study Evaluating LB1148

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio, Inc. has completed a Composite Units Offering in the amount of $12 million.

Palisade Bio, Inc. Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio Initiates Phase 3 Study of Lb1148 in Lead Indication for Postoperative Return of Bowel Function

Palisade Bio, Inc. Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard

Palisade Bio, Inc. announced a financing transaction

Palisade Bio, Inc. and Newsoara Biopharma Co., Ltd. Receives NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148

High number of new directors

Palisade Bio, Inc., Annual General Meeting, Jun 09, 2022

Palisade Bio, Inc. Appoints Robert McRae as Senior Vice President, Operations and Strategic Development

Palisade Bio to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

High number of new and inexperienced directors

Palisade Bio, Inc. announced that it has received $5.209141 million in funding from Yuma Regional Medical Center

Palisade Bio, Inc. announced delayed 10-Q filing

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Palisade Bio, Inc. Riepilogo dei fondamenti